GSK remains confident of approval despite the delay, with hopes of blockbuster sales for its myelofibrosis candidate.
GSK will have to wait three months longer for the US Food and Drug Administration to make a ruling on its myelofibrosis candidate momelotinib, with the agency pushing back its decision date to 16 September.
The UK-headquartered pharma company announced the delay on 16 June, the same day the regulator had originally pencilled in to...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
